Innovative Healthcare, Led by DEJIAN: Patented Products Featured at the 3rd Global Digital Trade Expo
Valgen Medtech
Minimally Invasive Interventional Device Developer
Recently, the Third Global Digital Trade Expo (Digital Trade Fair) successfully concluded in Hangzhou, Zhejiang, China.The 2nd China Patent-Intensive Products Exhibition (PIPF), as a core section, brought together 320 leading enterprises from 15 provinces and cities across China, showcasing over 500 cutting-edge innovative products. Invited by the Hangzhou High-tech Industrial Development Zone (Binjiang) Market Supervision Administration (Intellectual Property Office), Valgen Medtech Co., Ltd. participated in the exhibition for the first time with multiple innovative products that have independent intellectual property rights and are made in China., fully showcasing the outstanding achievements of enterprises in technological innovation and R&D, and demonstrating the firm determination to support the high-quality development of China's technology-driven healthcare system.
The China Patent-Intensive Products Exhibition, jointly hosted by the China Patent Protection Association, Zhejiang Provincial Market Supervision Administration (Provincial Intellectual Property Office), and Hangzhou Municipal People's Government, was organized by the Hangzhou Intellectual Property Office and Xiaoshan District People's Government of Hangzhou, with strong support from the National Intellectual Property Administration, intellectual property offices of participating provinces, and the organizing committee of the Third Global Digital Trade Expo.Valgen Medtech's exhibit, the DragonFly™ Transcatheter Mitral Valve Clip System, stands out in the field of advanced medical equipment for interventional cardiac valve disease. With technological innovation and upgrades, it promotes the development of structural heart interventions in China, breaks international monopolies, and improves the quality of life and health for patients.
As a "Specialized, Precise, Unique, and Innovative" enterprise in Zhejiang ProvinceValgen Medtech has always been at the forefront of innovation and intellectual property in the industry. The company adheres to the solid accumulation of core technologies and meets the requirements of practical innovation and technical upgrades.Currently, it has over 600 patent applications, including more than 200 authorized invention patents.Valgen Medtech has successively won the second prize in the first China Biomedical Industry High-Value Patent Cultivation Competition and the third prize in the "Golden Panda" High-Value Patent Cultivation Competition, both national-level awards of significant importance within the industry. It also undertook the 2023 Binjiang District Industrial Planning Patent Navigation Project, which was successfully completed, fully leveraging the strategic empowerment role of intellectual property in technological innovation., further proving the significance of being an industry-leading exemplar.
The launch of Valgen Medtech's DragonFly™ system addresses urgent medical challenges currently faced in China, particularly mitral regurgitation, a disease with high incidence rates and significant societal impact. According to the "Clinical Pathway for Transcatheter Mitral Valve Edge-to-Edge Repair in China (2022 Full Text Version)," the prevalence of mitral regurgitation in individuals aged 65 and above in China is as high as 19.1% among those with moderate to severe valvular heart disease. Over two-thirds of these patients are unable to undergo surgical treatment due to advanced age, comorbidities, and other risk factors, resulting in a 5-year mortality rate as high as 50%.The DragonFly™ system successfully破解了这一外科难题through transcatheter interventional surgery and improved treatment outcomes through technological innovation., providing a new treatment option for approximately 7.5 million mitral regurgitation patients in China and significantly improving their quality of life.Currently, the system has benefited nearly a thousand patients with mitral valve disease in China and has successfully expanded into overseas markets.`, winning widespread acclaim.`
For many years, Valgen Medtech has continuously invested in research and development and intellectual property, focusing on strengthening the cultivation and development of patent-intensive products, enhancing technological innovation and upgrading, and fully leveraging its advantages and bridging role in the global market. With intellectual property as the driving force, Valgen Medtech will continue to boost the innovative development of China's high-end medical device industry, contributing more "Chinese wisdom" and "Chinese strength" to the health of patients worldwide.
Valgen Medtech Co., Ltd. was founded in 2015 and focuses on interventional treatment products and technologies for mitral and tricuspid valve diseases. The company has applied for over 600 patents globally, with more than 200 already authorized. Four innovative products developed independently have passed the special review process for innovative medical devices by the pharmaceutical regulatory authority. Its range of interventional treatment devices, represented by the Dragon series, will greatly enrich clinical options in China for treating structural heart diseases.
Core Product DragonFly™ Transcatheter Mitral Valve Clip System — As the first transvenous edge-to-edge repair product independently developed in China, it has been approved by the NMPA for formal launch in China. The product is supported by the National Key R&D Program of China's "14th Five-Year Plan." In addition, other currently marketed products include Sister Pu™ Medical Radiation Protection Screen, Magpie™ Balloon Dilation Catheter, DragonPath™ Atrial Septal Puncture System, and a series of guidewires.